1795 Share Price Performance
NT$0
-214.00 (-100.00%)
Price NT$0
Fair ValueNT$367.00
Share Pricen/a
Narrative Update • Jun 25
Lotus Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
1795 Community Narratives
AN
Fair Value
·Fair Value NT$367 44.1% undervalued intrinsic discount
Analysts Reaffirm Lotus Pharmaceutical Price Target Amid Stable Growth and Profitability Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value NT$200 2.5% overvalued intrinsic discount
Trade And Regulation Will Shrink Margins Yet Southeast Asia Aids
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value NT$500 59.0% undervalued intrinsic discount
Hybrid Pipeline Expansion Will Harness Aging Trends Amid Cost Headwinds
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Trade And Regulation Will Shrink Margins Yet Southeast Asia Aids
Lotus Pharmaceutical is pushing into Southeast Asia and higher-complexity generic medicines, which could open new growth paths as global demand for affordable drugs rises. But heavier regulation, trade barriers, and reliance on a handful of key products in the U.S. could squeeze profits and make results bumpier than investors expect.Read more
AN
NT$200
2.5% overvalued intrinsic discount
Fair Value
Revenue
32.61% p.a.
Profit Margin
12.51%
Future PE
8.67x
Price in 2029
NT$235.49
Analysts Reaffirm Lotus Pharmaceutical Price Target Amid Stable Growth and Profitability Outlook
Lotus Pharmaceutical is pushing for faster growth by buying regional businesses and bringing more manufacturing in-house, aiming to expand across Southeast Asia while widening its medicine lineup. The big question is whether it can pull off these deals and new product launches without being tripped up by setbacks like integration issues, product dependence, or currency swings.Read more
AN
NT$367
44.1% undervalued intrinsic discount
Fair Value
Revenue
35.69% p.a.
Profit Margin
11.15%
Future PE
21.92x
Price in 2029
NT$429.25
Hybrid Pipeline Expansion Will Harness Aging Trends Amid Cost Headwinds
Lotus Pharmaceutical is turning recent deal integrations into fast growth across Southeast Asia, while using its own manufacturing and new product launches to lift profitability. The big question is whether that momentum can outlast rising competition, higher research spending, and heavy dependence on a small number of cancer medicines.Read more
AN
NT$500
59.0% undervalued intrinsic discount
Fair Value
Revenue
34.64% p.a.
Profit Margin
16.92%
Future PE
20.09x
Price in 2029
NT$583.34
Trending Discussion
Recently Updated Narratives
AN
1795: Complex Generics Expansion And Lower Margins Will Shape Future P E Outlook
Fair Value: NT$200 2.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
1795: Global Complex Generics Launch Will Drive Future Repricing
Fair Value: NT$367 44.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
1795: Expanded Respiratory Launch Will Support Higher Future Margins
Fair Value: NT$500 59.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lotus Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 14.66
- 54.77%
- 15.77%
- 231.8%
About 1795
- Founded
- 1966
- Employees
- n/a
- CEO
- WebsiteView website
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
Recent 1795 News & Updates
Narrative Update • Jun 08
1795: Global Complex Generics Launch Will Drive Future Repricing
Analysts now set a slightly lower price target for Lotus Pharmaceutical, trimming it by about NT$1 while adjusting their assumptions on discount rate, revenue growth, profit margin, and future P/E to reflect a more balanced view of the stock. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.
Narrative Update • May 25
